ArticleJournal of neuro-oncology2008
Medulloblastoma in children: a 32-year experience from a single institution.
Article in Journal of neuro-oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- The clinical importance of medulloblastoma extent of resection: a systematic review.Journal of neuro-oncology · 2018Pooled it
- Significance of Early Proton Beam Therapy Initiation in Achieving Complete Response in Pediatric Medulloblastoma: A Retrospective Study.Cancer medicine · 2026Article
- Evolution of neurosurgical advances and nuances in medulloblastoma therapy.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024Review
- Impact of treatment and clinical characteristics on the survival of children with medulloblastoma in Mexico.Frontiers in oncology · 2024Article
- Molecular Subgroup Is the Strongest Predictor of Medulloblastoma Outcome in a Resource-Limited Country.JCO global oncology · 2021Article
- Management and outcomes of treating pediatric medulloblastoma: an eight years' experience in an Iranian pediatric center.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2018Article
- Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.The Lancet. Oncology · 2016Article
- The Ketogenic Diet Does Not Affect Growth of Hedgehog Pathway Medulloblastoma in Mice.PloS one · 2015Article
- Temozolomide in relapsed pediatric brain tumors: 14 cases from a single center.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2012Article
- Web-based survey of resources for treatment and long-term follow-up for children with brain tumors in developing countries.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2011Article
- New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence.Pharmacology & therapeutics · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We retrospectively evaluated 203 patients newly diagnosed with medulloblastoma between 1975 and 2006. All patients underwent surgical resection and after surgery were treated with a combination of radiotherapy and chemotherapy. CCNU-based protocols were used in the early years, with CDDP+VP16 being used more recently. Radiotherapy was used in patients older than three years of age according to the protocols. One hundred fifteen patients had total surgical resection, 78 had subtotal resection, and 4 patients had only a biopsy. Every patient received chemotherapy: 124 with the CCNU-based protocol, 75 with CDDP+VP16, and 4 with other protocols. Overall (OS) and event free-survival (EFS) rates were 43.1 and 41.9% in the whole group, with a median follow-up time of 8 years. OS rates for patients with and without spinal seeding were 30 and 63.1% (P = 0.0002). OS rates for males and females were 36.2 and 54.7% (P = 0.03). OS rates for patients receiving the CCNU and CDDP+VP16 protocols were 41.1 and 45%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.